Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Account Payables (2016 - 2025)

Enanta Pharmaceuticals' Change in Account Payables history spans 14 years, with the latest figure at -$63000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 62.5% year-over-year to -$63000.0; the TTM value through Dec 2025 reached -$1.2 million, up 79.05%, while the annual FY2025 figure was -$1.3 million, 216.67% down from the prior year.
  • Change in Account Payables reached -$63000.0 in Q4 2025 per ENTA's latest filing, up from -$723000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.6 million in Q1 2023 to a low of -$5.1 million in Q2 2022.
  • Average Change in Account Payables over 5 years is -$218700.0, with a median of -$623000.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: soared 1796.21% in 2021, then tumbled 2923.33% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$1.7 million in 2021, then surged by 58.75% to -$686000.0 in 2022, then soared by 854.23% to $5.2 million in 2023, then plummeted by 103.25% to -$168000.0 in 2024, then soared by 62.5% to -$63000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Change in Account Payables are -$63000.0 (Q4 2025), -$723000.0 (Q3 2025), and -$1.3 million (Q2 2025).